Summary
We describe the protocols of using siRNAs, or shRNAs delivered by a lentiviral vector, as a means to silence cancer-causing genes. We use cervical cancer as a model to demonstrate the inhibition of the human papillomavirus (HPV) oncogenes E6 and E7 in cervical cancer cells by RNAi and inhibition of the cell growth in vitro and tumor growth in mouse models. The protocols include methods on siRNA and shRNA design, production of lentiviral-vectored shRNA, transfection or transduction of cervical cancer cells with siRNA or shRNA, and detection of the inhibitory effects of siRNA or shRNA both in vitro and in vitro.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Bitko, V., Musiyenko, A., Shulyayeva, O., and Barik, S. (2005). Inhibition of respiratory viruses by nasally administered siRNA. Nat. Med. 11, 50–55.
Capodici, J., Kariko, K., and Weissman, D. (2002). Inhibition of HIV-1 infection by small interfering RNA-mediated RNA interference. J. Immunol. 169, 5196–5201.
Dasgupta, R., and Perrimon, N. (2004). Using RNAi to catch Drosophila genes in a web of interactions: Insights into cancer research. Oncogene 23, 8359–8365.
Hannon, G. J., and Rossi, J. J. (2004). Unlocking the potential of the human genome with RNA interference. Nature 431, 371–378.
Jacque, J. M., Triques, K., and Stevenson, M. (2002). Modulation of HIV-1 replication by RNA interference. Nature 418, 435–438.
Meister, G., and Tuschl, T. (2004). Mechanisms of gene silencing by double-stranded RNA. Nature 431, 343–349.
Check, E. (2005). Pioneering HIV treatment would use interference and gene therapy. Nature 437, 601.
Humeau, L. M., Binder, G. K., Lu, X., et al. (2004). Efficient lentiviral vector-mediated control of HIV-1 replication in CD4 lymphocytes from diverse HIV+ infected patients grouped according to CD4 count and viral load. Mol. Ther. 9, 902–913.
Scherr, M., and Eder, M. (2002). Gene transfer into hematopoietic stem cells using lentiviral vectors. Curr. Gene Ther. 2, 45–55.
Check, E. (2005). A crucial test. Nat. Med. 11, 243–244.
Raoul, C., Abbas-Terki, T., Bensadoun, J. C., et al. (2005). Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS. Nat. Med. 11, 423–428.
Ralph, G. S., Radcliffe, P. A., Day, D. M., et al. (2005). Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model. Nat. Med. 11, 429–433.
zur Hausen, H. (2002). Papillomaviruses and cancer: From basic studies to clinical application. Nat. Rev. Cancer 2, 342–350.
DiPaolo, J. A., and Alvarez-Salas, L. M. (2004). Advances in the development of therapeutic nucleic acids against cervical cancer. Expert Opin. Biol. Ther. 4, 1251–1264.
Parkin, D. M., Bray, F. I., and Devesa, S. S. (2001). Cancer burden in the year 2000. The global picture. Eur. J. Cancer 37, S4–S66.
Goodwin, E. C., and DiMaio, D. (2000). Repression of human papillomavirus oncogenes in HeLa cervical carcinoma cells causes the orderly reactivation of dormant tumor suppressor pathways. Proc. Natl. Acad. Sci. USA 97, 12513–12518.
Munger, K., Werness, B. A., Dyson, N., Phelps, W. C., Harlow, E., and Howley, P. M. (1989). Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product. EMBO J. 8, 4099–4105.
von Knebel Doeberitz, M., Oltersdorf, T., Schwarz, E., and Gissmann, L. (1988). Correlation of modified human papilloma virus early gene expression with altered growth properties in C4–1 cervical carcinoma cells. Cancer Res. 48, 3780–3786.
Putral, L., Bywater, M., Gu, W., et al. (2005). RNAi against HPV oncogenes in cervical cancer cells results in increased sensitivity to cisplatin. Mol. Pharmacol. 68, 1311–1319.
Butz, K., Ristriani, T., Hengstermann, A., Denk, C., Scheffner, M., and Hoppe-Seyler, F. (2003). siRNA targeting of the viral E6 oncogene efficiently kills human papillomavirus-positive cancer cells. Oncogene 22, 5938–5945.
Hall, A. H., and Alexander, K. A. (2003). RNA interference of human papillomavirus type 18 E6 and E7 induces senescence in HeLa cells. J. Virol. 77, 6066–6069.
Jiang, M., and Milner, J. (2002). Selective silencing of viral gene expression in HPV-positive human cervical carcinoma cells treated with siRNA, a primer of RNA interference. Oncogene 21, 6041–6048.
Jiang, M., Rubbi, C. P., and Milner, J. (2004). Gel-based application of siRNA to human epithelial cancer cells induces RNAi-dependent apoptosis. Oligonucleotides 14, 239–248.
Yoshinouchi, M, Yamada, T., Kizaki, M., et al. (2003). In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by E6 siRNA. Mol. Ther. 8, 762–768.
Yamato, K., Fen, J., Kobuchi, H., et al. (2006). Induction of cell death in human papillomavirus 18-positive cervical cancer cells by E6 siRNA. Cancer Gene Ther. 13, 234–241.
Schiffelers, R. M., Ansari, A., Xu, J., et al. (2004). Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res. 32, e149.
Zimmermann, T. S., Lee, A. C., Akinc, A., et al. (2006). RNAi-mediated gene silencing in non-human primates. Nature 441, 111–114.
Sioud, M., and Sorensen, D.R. (2003). Cationic liposome-mediated delivery of siRNAs in adult mice. Biochem. Biophys. Res. Commun. 312, 1220–1225.
Bai, Y., Soda, Y., Izawa, K., et al. (2003). Effective transduction and stable transgene expression in human blood cells by a third-generation lentiviral vector. Gene Ther. 10, 1446–1457.
Van den Haute, C., Eggermont, K., Nuttin, B., Debyser, Z., and Baekelandt. V. (2003). Lentiviral vector-mediated delivery of short hairpin RNA results in persistent knockdown of gene expression in mouse brain. Hum. Gene Ther. 14, 1799–1807.
Kafri, T., van Praag, H., Gage, F. H., and Verma, I. M. (2000). Lentiviral vectors: Regulated gene expression. Mol. Ther. 1, 516–521.
Miyoshi, H., Blomer, U., Takahashi, M., Gage, F. H., and Verma, I. M. (1998). Development of a self-inactivating lentivirus vector. J. Virol. 72, 8150–8157.
Naldini, L., and Verma, I. M. (2000). Lentiviral vectors. Adv. Virus Res. 55, 599–609.
van der Wegen, P., Louwen, R., Imam, A. M., et al. (2006). Successful treatment of UGT1A1 deficiency in a rat model of Crigler–Najjar disease by intravenous administration of a liver-specific lentiviral vector. Mol. Ther. 13, 374–381.
Morizono, K., Xie, Y., Ringpis, G. E., et al. (2005). Lentiviral vector retargeting to P-glycoprotein on metastatic melanoma through intravenous injection. Nat. Med. 11, 346–352.
Yanez-Munoz, R. J., Balaggan, K. S., MacNeil, A., et al. (2006). Effective gene therapy with nonintegrating lentiviral vectors. Nat. Med. 12, 348–353.
Kimchi-Sarfaty, C., Brittain, S., Garfield, S., Caplen, N. J., Tang, Q., and Gottesman, M. M. (2005). Efficient delivery of RNA interference effectors via in vitro-packaged SV40 pseudovirions. Hum. Gene Ther. 16, 1110–1115.
Dull, T., Zufferey, R., Kelly, M., et al. (1998). A third-generation lentivirus vector with a conditional packaging system. J. Virol. 72, 8463–8471.
Brummelkamp, T. R., Bernards, R., and Agami, R. (2002). A system for stable expression of short interfering RNAs in mammalian cells. Science 296, 550–553.
Jazag, A., Kanai, F., Ijichi, H., et al. (2005). Single small-interfering RNA expression vector for silencing multiple transforming growth factor-beta pathway components. Nucleic Acids Res. 33, e131.
Gu, W., Putral, L., Hengst, K., et al. (2006). Inhibition of cervical cancer cell growth in vitro and in vivo with lentiviral-vector delivered short hairpin RNA targeting human papillomavirus E6 and E7 oncogenes. Cancer Gene Ther. 13, 1023–1032.
Chomczynski, P., and Sacchi, N. (1987). Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162, 156–159.
Gu, W., Janssens, P., Holland, M., Seamark, R., and Kerr, P. (2005). Lymphocytes and MHC class II positive cells in the female rabbit reproductive tract before and after ovulation. Immunol. Cell Biol. 83, 596–606.
Acknowledgment
The research work was supported by a grant from the National Health and Medical Research Council and by a Peter Doherty Postdoctoral Fellowship award.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Humana Press, a part of Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Gu, W., Putral, L., McMillan, N. (2008). siRNA and shRNA as Anticancer Agents in a Cervical Cancer Model. In: Barik, S. (eds) RNAi. Methods in Molecular Biology™, vol 442. Humana Press. https://doi.org/10.1007/978-1-59745-191-8_12
Download citation
DOI: https://doi.org/10.1007/978-1-59745-191-8_12
Publisher Name: Humana Press
Print ISBN: 978-1-58829-874-4
Online ISBN: 978-1-59745-191-8
eBook Packages: Springer Protocols